Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for '3tc-Lpv'
3tc-Lpv published presentations and documents on DocSlides.
Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial
by ricardo
ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-T...
Switch to DRV/r + 3TC DUAL Study
by jireh
DRV/r 800/100 + 3TC 300 QD. N = 126. N = 123. DRV/...
Switch to DOR-TDF-3TC vs. Continued Baseline Regimen
by dorothy
DRIVE SHIFT. Switch to Doravirine-TDF-3TC versus C...
EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC
by felicity
ACTG 5202. EFV versus ATV/r, both with ABC-3TC or ...
SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN
by jacey
1. ViiV Healthcare, Brentford, UK; . 2. Centre Hos...
DTG/3TC 1st line (GEMINI)
by oryan
ARV . strategies. DOR > DRV/r 1st line. (DRIVE-...
DTG + 3TC versus DTG + TDF-FTC as Initial ART
by della
GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . v...
DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT
by jasmine
–. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RE...
Switch to DTG/3TC TANGO Design
by lam
Endpoints. Primary: proportion of patients with HI...
Switch a ATV/r 3TC Estudio ATLAS-M
by pamella-moone
ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N =...
Switch to PI/r + 3TC
by lois-ondreau
vs. PI/r . monotherapy. Study PIVOT. Study MOBID...
Switch to DTG/ABC/3TC
by karlyn-bohler
STRIIVING . Study. Design. Endpoints. Primary: pr...
Cases from the Clinic(ians): Case-based Panel Discussion
by tripp
Associate Dean for Global Health. University of Al...
ClinicalTrials.gov
by lauren
Identifier: . NCT02770508 . Dual therapy based on ...
HIV 2020: Time for change
by garcia
Dr. Kay Mahomed. Netcare. Garden City Clinic. Ma...
CHIDAMIDE DISRUPTS AND REDUCES HIV-1 LATENCY IN PATIENTS ON SUPPRESSIVE ANTIRETROVIRAL THERAPY
by sophie
Y. . S. un, J. Li, J. Ma, C. Wang, F. Bai, K. Zhao...
ADDP Training Programme Community Retail Pharmacy Drug Distribution Points
by jocelyn
(CRPDDP). Training Contents. Module 1. : . HIV Ove...
Dolutegravir-Lamivudine (
by audrey
Dovato. ). Last Updated: November 28, 2022. Prepar...
What’s new in the 2019 WHO Guidelines:
by elina
Dolutegravir based regimens in first- ad second-li...
Meg Doherty MD MPH PhD 23 July 2018
by jordyn
WHO HQ. The role of DTG based regimens in first- a...
Monday, 23 July, 10:15-12:15
by della
Hall 11B, RAI Amsterdam. Uptake and Procurement of...
Interactive ART Cases From the Clinic: Is There One Right Answer?
by megan
Joseph J. Eron, Jr, MD. Professor of Medicine. Uni...
WHO ARV Forecasting Meeting
by sistertive
Geneva, March 19 - 20 , 2015 1 | Treatment and C...
Comparison of INSTI vs EFV
by mediumgeneral
STARTMRK. GS-US-236-0102 . SINGLE. Walmsley. S. N...
Eric S. Daar , MD Professor of Medicine
by faustina-dinatale
David Geffen School of Medicine. at University of...
1 Fundación Huésped, Buenos Aires, Argentina;
by aaron
2. Instituto Nacional de Ciencias Médicas y Nutr...
Fixed-Dose Combination of
by myesha-ticknor
Doravirine. /Lamivudine/TDF is Non-Inferior to . ...
Eric S. Daar , MD Professor of Medicine
by faustina-dinatale
David Geffen School of Medicine. at University of...
Treatment of Children and Adolescents
by liane-varnes
Implementation Challenges. Annette H. Sohn, MD. T...
ART Initiation in Resource-Limited Settings
by lois-ondreau
Susan M. Graham . Assistant Professor, Medicine a...
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG A5257. WAVES. ARIA . ...
Rationalizing Pediatric ARV Formularies:
by marina-yarberry
The IATT Optimal Pediatric ARV List. . Presented...
Switch from Efavirenz + ZDV-3TC to Efavirenz + TDF-FTC
by ramon803
SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEE...
Updates on Individual and Universal HIV Treatment Strategies
by norah
EECA INTERACT, November 19, 2019. Stefan Baral, MD...
Optimization of Antiretroviral Therapy
by belinda
With Emergence of Comorbidities. Roger J. . Bedimo...
Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine
by kylie
STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine ...
Thinking of Now and Tomorrow: Emerging Treatment Paradigms
by deena
Pedro Cahn. Disclosures. Advisory. . boards. : Me...
Introduction Characteristics, Treatment Patterns,
by cappi
and . Virologic. Outcomes . for Treatment-experie...
IAS – USA Fall New York Course: Case Discussion
by jalin
Luke . Jerram. Disclosures: Educational grant supp...
Eric S. Daar , MD Michael S.
by ButterflyHeart
Saag. , MD. Antiretroviral Therapy:. A Case-Based ...
Load More...